Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05270499 · ClinicalTrials.gov registry record

Aveir VR Real-World Evidence Post-Approval Study

A clinical trial of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.

Recruiting
Registry status
2,100
Enrollment target
1
Study location

NCT05270499: Recruiting study of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.

NCT05270499 is a study of Bradycardia and Arrythmia that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 2,100 participants, below the 4,340-participant average among 29 other Bradycardia trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05270499, a study of Bradycardia and Arrythmia, is actively recruiting participants, sponsored by Abbott Medical Devices.

RECRUITING
Registry status
2,100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this post-approval study is to evaluate the long-term safety of the single-chamber Aveir VR leadless pacemaker using real-world evidence methods.

Primary Outcome

Freedom from complications through 30 days post implant procedure

Interventions

  • DEVICE Aveir VR Leadless Pacemaker System

Study Locations (1)

California

  • Abbott - Sylmar

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 2022-06-21
Est. Completion 2034-02-28
Abbott Medical Devices

261 total trials

What NCT05270499 shows while recruiting

NCT05270499 is an observational study that tracks outcomes without assigning an intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, below the 4,340-participant average among 29 other Bradycardia trials with a reported enrollment target (52% lower).

The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Aveir VR Leadless Pacemaker System is the first listed.

NCT05270499 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05270499 about?

NCT05270499 is a clinical study titled "Aveir VR Real-World Evidence Post-Approval Study". The purpose of this post-approval study is to evaluate the long-term safety of the single-chamber Aveir VR leadless pacemaker using real-world evidence methods.

What is the current status of trial NCT05270499?

This trial is currently recruiting. The enrollment target is 2,100 participants. The study started on 2022-06-21. Estimated completion is 2034-02-28.

What conditions does trial NCT05270499 study?

This clinical trial studies the following conditions: Bradycardia, Arrythmia, Cardiac Pacemaker.

What interventions are being tested in trial NCT05270499?

The interventions under investigation include: Aveir VR Leadless Pacemaker System (DEVICE).

Who is sponsoring clinical trial NCT05270499?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05270499 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bradycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05270499's enrollment target sits among peer trials

2,100 9th of 29 higher than 21 of 29 other Bradycardia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04649242 · 2,100 participants · Phase 3

    Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  • NCT05206331 · 2,100 participants · Phase 4

    CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

  • NCT06324981 · 2,100 participants · NA

    Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors

  • NCT06482957 · 2,100 participants

    Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05270499, the US trial registry maintained by the National Library of Medicine. NCT05270499 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.